Detalhe da pesquisa
1.
Frontline Treatment of Mantle Cell Lymphoma.
Blood
; 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38498174
2.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Blood
; 142(7): 621-628, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319432
3.
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Blood
; 139(8): 1147-1159, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34428285
4.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood
; 140(21): 2193-2227, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001803
5.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood
; 140(11): 1229-1253, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653592
6.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol
; 103(1): 185-198, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851072
7.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Blood
; 138(6): 427-438, 2021 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827139
8.
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.
Blood
; 137(10): 1353-1364, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871584
9.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
; 21(11): 1118-1131, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935098
10.
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.
J Am Acad Dermatol
; 88(6): 1271-1281, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870917
11.
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
JAMA
; 330(6): 528-536, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552303
12.
Putting the Heme Back in Heme-Onc: an Evaluation of the Redesigned Hematology Track within the Dana Farber/Mass General Brigham Hematology-Oncology Fellowship.
J Cancer Educ
; 38(2): 691-696, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35596109
13.
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Lancet Oncol
; 22(10): 1391-1402, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534514
14.
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Blood
; 134(7): 606-613, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31186274
15.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
Blood
; 134(15): 1238-1246, 2019 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31331918
16.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Blood
; 134(1): 22-29, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952672
17.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
J Natl Compr Canc Netw
; 19(11): 1218-1230, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34781267
18.
Improved survival in cHL with novel agents.
Blood
; 141(22): 2666-2668, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37261856
19.
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 131(11): 1183-1194, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229594
20.
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
Blood
; 132(1): 40-48, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703778